Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORAL SUSPENSIONGeneric

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE

Standard Dose
30MG; 50MG; 60MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE is listed in Drugs@FDA under application 203076 (NDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE Form and strength TABLET; ORAL SUSPENSION - 30MG; 50MG; 60MG Sponsor CIPLA LTD Submission history Latest submission status date: 2012-10-16 00:00:00.

Structured Monograph

Clinical summary

Approval overview LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE is listed in Drugs@FDA under application 203076 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE Form and strength TABLET; ORAL SUSPENSION - 30MG; 50MG; 60MG Sponsor CIPLA LTD Submission history Latest submission status date: 2012-10-16 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.